Logo image of DTIL

PRECISION BIOSCIENCES INC (DTIL) Stock Fundamental Analysis

NASDAQ:DTIL - Nasdaq - US74019P2074 - Common Stock - Currency: USD

5.89  +0.24 (+4.25%)

After market: 5.89 0 (0%)

Fundamental Rating

2

Taking everything into account, DTIL scores 2 out of 10 in our fundamental rating. DTIL was compared to 571 industry peers in the Biotechnology industry. DTIL may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, DTIL is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

DTIL had negative earnings in the past year.
DTIL had a negative operating cash flow in the past year.
DTIL had negative earnings in each of the past 5 years.
DTIL had a negative operating cash flow in each of the past 5 years.
DTIL Yearly Net Income VS EBIT VS OCF VS FCFDTIL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M -100M

1.2 Ratios

The Return On Assets of DTIL (5.63%) is better than 95.20% of its industry peers.
DTIL has a better Return On Equity (13.29%) than 96.27% of its industry peers.
Industry RankSector Rank
ROA 5.63%
ROE 13.29%
ROIC N/A
ROA(3y)-33.24%
ROA(5y)-42.36%
ROE(3y)-181.13%
ROE(5y)-171.18%
ROIC(3y)N/A
ROIC(5y)N/A
DTIL Yearly ROA, ROE, ROICDTIL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 100 -100 -200 -300

1.3 Margins

DTIL has a better Profit Margin (11.48%) than 95.56% of its industry peers.
The Operating Margin and Gross Margin are not available for DTIL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 11.48%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DTIL Yearly Profit, Operating, Gross MarginsDTIL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300 -400

More info and screens

3

2. Health

2.1 Basic Checks

DTIL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, DTIL has more shares outstanding
The number of shares outstanding for DTIL has been increased compared to 5 years ago.
Compared to 1 year ago, DTIL has a worse debt to assets ratio.
DTIL Yearly Shares OutstandingDTIL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M
DTIL Yearly Total Debt VS Total AssetsDTIL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -3.02, we must say that DTIL is in the distress zone and has some risk of bankruptcy.
DTIL's Altman-Z score of -3.02 is in line compared to the rest of the industry. DTIL outperforms 46.89% of its industry peers.
DTIL has a Debt/Equity ratio of 0.34. This is a healthy value indicating a solid balance between debt and equity.
DTIL has a worse Debt to Equity ratio (0.34) than 73.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF N/A
Altman-Z -3.02
ROIC/WACCN/A
WACC10.06%
DTIL Yearly LT Debt VS Equity VS FCFDTIL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 9.22 indicates that DTIL has no problem at all paying its short term obligations.
DTIL's Current ratio of 9.22 is fine compared to the rest of the industry. DTIL outperforms 76.91% of its industry peers.
DTIL has a Quick Ratio of 9.22. This indicates that DTIL is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of DTIL (9.22) is better than 77.09% of its industry peers.
Industry RankSector Rank
Current Ratio 9.22
Quick Ratio 9.22
DTIL Yearly Current Assets VS Current LiabilitesDTIL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

DTIL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 89.95%, which is quite impressive.
The Revenue has grown by 43.62% in the past year. This is a very strong growth!
DTIL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 34.96% yearly.
EPS 1Y (TTM)89.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.14%
Revenue 1Y (TTM)43.62%
Revenue growth 3Y26.13%
Revenue growth 5Y34.96%
Sales Q2Q%-95.61%

3.2 Future

DTIL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.17% yearly.
The Revenue is expected to decrease by -7.80% on average over the next years.
EPS Next Y116.58%
EPS Next 2Y28.78%
EPS Next 3Y20.72%
EPS Next 5Y11.17%
Revenue Next Year35.59%
Revenue Next 2Y-38.72%
Revenue Next 3Y-15.89%
Revenue Next 5Y-7.8%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
DTIL Yearly Revenue VS EstimatesDTIL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 20M 40M 60M 80M 100M
DTIL Yearly EPS VS EstimatesDTIL Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DTIL. In the last year negative earnings were reported.
Also next year DTIL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DTIL Price Earnings VS Forward Price EarningsDTIL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DTIL Per share dataDTIL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

DTIL's earnings are expected to grow with 20.72% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.78%
EPS Next 3Y20.72%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DTIL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PRECISION BIOSCIENCES INC

NASDAQ:DTIL (2/20/2025, 8:12:14 PM)

After market: 5.89 0 (0%)

5.89

+0.24 (+4.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2024-11-04/bmo
Earnings (Next)03-25 2025-03-25/amc
Inst Owners39.31%
Inst Owner Change-2.92%
Ins Owners3.03%
Ins Owner Change0.97%
Market Cap46.47M
Analysts84
Price Target34.27 (481.83%)
Short Float %11.39%
Short Ratio1.33
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)194.74%
Min EPS beat(2)-14.74%
Max EPS beat(2)404.22%
EPS beat(4)2
Avg EPS beat(4)94.28%
Min EPS beat(4)-94.4%
Max EPS beat(4)404.22%
EPS beat(8)5
Avg EPS beat(8)59.01%
EPS beat(12)7
Avg EPS beat(12)40.82%
EPS beat(16)10
Avg EPS beat(16)29.76%
Revenue beat(2)1
Avg Revenue beat(2)180.64%
Min Revenue beat(2)-91.12%
Max Revenue beat(2)452.4%
Revenue beat(4)2
Avg Revenue beat(4)125.73%
Min Revenue beat(4)-91.12%
Max Revenue beat(4)452.4%
Revenue beat(8)6
Avg Revenue beat(8)106.74%
Revenue beat(12)7
Avg Revenue beat(12)64.37%
Revenue beat(16)10
Avg Revenue beat(16)93.85%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)5.04%
EPS NQ rev (3m)2.44%
EPS NY rev (1m)42.23%
EPS NY rev (3m)34900%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-12.75%
Revenue NY rev (1m)-1.05%
Revenue NY rev (3m)-5.07%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.62
P/FCF N/A
P/OCF N/A
P/B 0.72
P/tB 0.72
EV/EBITDA N/A
EPS(TTM)-1.99
EYN/A
EPS(NY)-5.48
Fwd EYN/A
FCF(TTM)-6.13
FCFYN/A
OCF(TTM)-6.11
OCFYN/A
SpS9.52
BVpS8.22
TBVpS8.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 5.63%
ROE 13.29%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 11.48%
GM N/A
FCFM N/A
ROA(3y)-33.24%
ROA(5y)-42.36%
ROE(3y)-181.13%
ROE(5y)-171.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.09%
Cap/Sales 0.23%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.22
Quick Ratio 9.22
Altman-Z -3.02
F-Score5
WACC10.06%
ROIC/WACCN/A
Cap/Depr(3y)46.86%
Cap/Depr(5y)132.36%
Cap/Sales(3y)7.64%
Cap/Sales(5y)30.91%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)89.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.14%
EPS Next Y116.58%
EPS Next 2Y28.78%
EPS Next 3Y20.72%
EPS Next 5Y11.17%
Revenue 1Y (TTM)43.62%
Revenue growth 3Y26.13%
Revenue growth 5Y34.96%
Sales Q2Q%-95.61%
Revenue Next Year35.59%
Revenue Next 2Y-38.72%
Revenue Next 3Y-15.89%
Revenue Next 5Y-7.8%
EBIT growth 1Y60.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year83.56%
EBIT Next 3Y15.99%
EBIT Next 5Y10.49%
FCF growth 1Y6.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.25%
OCF growth 3YN/A
OCF growth 5YN/A